Formal lodgement of FDA submission for EchoSolv HF
Filed with ASX · · 2 pages · English
Summary by 6ix AI
EchoIQ Limited has formally lodged its FDA submission for EchoSolv HF, a heart failure clinical decision support software, via the FDA's premarket notification pathway. The submission includes results from a clinical validation study conducted with Mayo Clinic, demonstrating high sensitivity and specificity in detecting heart failure. CEO Dustin Haines expressed satisfaction with the submission process and highlighted the potential market opportunities in the US healthcare sector. The company anticipates an FDA decision in the coming months, which could significantly impact its market presence.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from EchoIQ
- Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December
- Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results
- Exceptional Results from Validation Study for EchoSolv HF
- Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025
Later from EchoIQ
- Response to ASX Price Query
- Quarterly Activities Report and Appendix 4C Cash Flow Report
- Appendix 4D 31 December 2025
- S&P DJI Announces March 2026 Quarterly Rebalance
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
Follow EchoIQ into a list and get an email when it puts out news.
Follow EchoIQ